M3 subtype muscarinic receptors (CHRM3) are over-expressed in colon cancer. In this study, we used Apc min/1 mice to identify the role of Chrm3 expression in a genetic model of intestinal neoplasia, explored the role of Chrm3 in intestinal mucosal development and determined the translational potential of inhibiting muscarinic receptor activation. We generated Chrm3-deficient Apc min/1 mice and compared intestinal morphology and tumor number in 12-week-old Apcmin/1 Chrm3 2/2 and Apc min/1 Chrm3 1/1 control mice. Compared with Apc min/1 Chrm3 1/1 mice, Apc min/1 Chrm3 2/2 mice showed a 70 and 81% reduction in tumor number and volume, respectively (P < 0.01). In adenomas, b-catenin nuclear staining was reduced in Apc min/1 Chrm3 2/2 compared with Apc min/1 Chrm3 1/1 mice (P < 0.02). Whereas Apc gene mutation increased the number of crypt and Paneth cells and decreased villus goblet cells, these changes were absent in Apc min/1 Chrm3 2/2 mice. To determine whether pharmacological inhibition of muscarinic receptor activation attenuates intestinal neoplasia, we treated 6-week-old Apc min/1 mice with scopolamine butylbromide, a non-subtype-selective muscarinic receptor antagonist. After 8 weeks of continuous treatment, scopolamine butylbromide-treated mice showed a 22% reduction in tumor number (P 5 0.027) and a 36% reduction in tumor volume (P 5 0.004) as compared with control mice. Compared with Chrm3 gene ablation, the muscarinic antagonist was less efficacious, most probably due to shorter duration of treatment and incomplete blockade of muscarinic receptors. Overall, these findings indicate that interplay of Chrm3 and b-catenin signaling is important for intestinal mucosal differentiation and neoplasia and provide a proof-of-concept that pharmacological inhibition of muscarinic receptor activation can attenuate intestinal neoplasia in vivo.
Introduction
The muscarinic cholinergic family of G-protein-coupled receptors includes five subtypes designated M1R to M5R (gene names, CHRM1-CHRM5). In 1991, Gutkind et al. (1) reported that muscarinic receptors which activate downstream phosphatidylinositol hydrolysis (i.e. M1R, M3R, M5R) are conditional oncogenes when expressed in cells capable of proliferation. M3R are expressed widely in the gastrointestinal tract. Frucht et al. (2) reported that most human colon cancer cells robustly express M3R and CHRM3 messenger RNA expression was detected in all normal and neoplastic colon tissue tested (3) . Of greater interest, in 63% of colon cancers examined, CHRM3 expression was increased up to 8-fold compared with adjacent normal tissue (3) . Subsequently, we elucidated molecular mechanisms involving matrix metalloproteinase-mediated transactivation of epidermal growth factor receptors whereby muscarinic receptor activation stimulates human colon cancer cell proliferation (4, 5) . In human colon cancer cell lines and colon cancer tissue, we also demonstrated expression of choline acetyltransferase, a key enzyme required for production of the endogenous muscarinic agonist acetylcholine, and showed that colon cancer cells possess the ability to produce and release acetylcholine (6) . Collectively, these observations indicate that muscarinic receptor signaling plays an important role in intestinal neoplasia (7) .
To study growth factors and their receptors involved in intestinal neoplasia, two murine models are commonly used: azoxymethane-treated and Apc min/þ mice. Azoxymethane, a carcinogen, induces colon tumors with gross and microscopic features similar to human adenomas and adenocarcinomas (8) . We reported reduced number and size of both adenomas and adenocarcinomas in azoxymethane-treated Chrm3-deficient mice compared with azoxymethane-treated wild-type mice (9) .
Despite the utility of azoxymethane as a tool to induce intestinal neoplasia, this carcinogen also induces rodent liver injury which, at high doses, may be lethal (10) . Further, our recent work (10) indicates that deficiency or inactivation of Chrm3, the only muscarinic receptor subtype expressed in murine liver (11) , increases murine susceptibility to azoxymethane-induced hepatotoxicity, thereby limiting the utility of azoxymethane for studies of Chrm3 expression or activation in intestinal neoplasia. Because azoxymethane is activated by CYP2E1 in the liver (12) , altered azoxymethane metabolism in Chrm3-deficient mice may confound differential effects on colon neoplasia. Hence, we thought it important to confirm the role of Chrm3 expression and activation on intestinal neoplasia in a murine model, Apc min/þ mice, without potential confounding by liver injury from carcinogens like azoxymethane.
The commonly used Apc min/þ mouse model with a germ line mutation in the Apc gene recapitulates genetic changes associated with human colon cancer where 80% of tumors have an APC gene mutation and 10% have mutated b-catenin-both mutations activate Wnt/b-catenin signaling (13, 14) . In studies reported in the present communication, we used Apc min/þ mice to examine the effects of reducing Chrm3 expression and activation. In Apc min/þ mice, small intestinal tumors develop because the protein product of Apc gene mutation cannot participate in the scaffold that sequesters b-catenin for proteosomal degradation. This increases nuclear translocation of b-catenin and transcriptional activation of genes promoting intestinal epithelial cell proliferation (13, 15) . Treatment with a carcinogen is not necessary, thus avoiding confounding effects of azoxymethane-induced liver toxicity.
We hypothesized that reduced expression and activation of muscarinic receptors in Apc min/þ mice attenuates small intestinal neoplasia. To test this hypothesis, we generated Chrm3-deficient Apc min/þ mice and compared intestinal morphology and tumor number in 12-weekold Apc min/þ Chrm3 À/À and Apc min/þ Chrm3 þ/þ control mice. To determine whether pharmacological inhibition of muscarinic receptor activation attenuates intestinal neoplasia, we treated Apc min/þ mice with scopolamine butylbromide, a non-subtype-selective muscarinic receptor antagonist. Results of this in vivo work show the importance of muscarinic signaling for promotion of intestinal neoplasia, identify translational potential for reducing muscarinic receptor activation and reveal a role for muscarinic signaling in intestinal mucosal development.
Materials and methods

Animals
Male C57BL/6 Apc min/þ mice (Jackson Laboratory, Bar Harbor, ME) were crossed with female Chrm3 À/À mice on both C57BL/6 and 129S6/SvEv:CF1 (50%:50%)
Abbreviations: NBS, (-)-N-butylscopolamine; PBS, phosphate-buffered saline.
y These authors contributed equally to this work. Chrm3 À/À littermates identified by genotyping using polymerase chain reaction amplification of tail DNA. Chrm3 primers were M3-A3 (5#-aagaccacagtagcag tg-3#), M3-B (5#-ctctctacatccatagtccc-3#) and M 3 -NEO9 (5#-tggatgtggaatgtgtgcgagg-3#). To identify Apc min/þ mice, we used common primer MAPC15 (5#-ttccactttggcataagg-3#), WT primer MAPC9 (5#-gccatcccttcacgt tag-3#) and Min primer (5#-ttctgagaaagacagaagtta-3#) mixed in a single polymerase chain reaction (Jackson Labs protocol). Mice were bred, housed and treated under identical conditions in a pathogen-free room with free access to commercial rodent chow and water at the animal facility of the Baltimore Veterans Affairs Hospital. All experiments were approved by the Institutional Animal Care and Use Committee of the University of Maryland, Baltimore, and by the Research and Development Committee at the VA Maryland Health Care System.
Intestinal tumor measurement
At 12 weeks of age, male and female progeny of the above breeding schemes were euthanized and the small intestine was divided in three equal segments: proximal, middle and distal. Tumors were counted by an investigator masked to genotype and treatment using a dissecting microscope (Nikon SMZ1500). Tumor diameter was measured using Nikon Image-Pro (Image Pro International, Miami, FL) and tumor volume calculated: volume 5 1/2(length Â width 2 ) (9). Tissues were fixed with 10% neutral formalin and the distal third of small intestine prepared as Swiss rolls. Five-micron sections were prepared from paraffin-embedded tissues and stained with hematoxylin and eosin and Alcian blue, a mucin stain used to identify goblet cells.
Scopolamine butylbromide treatment
Six-week-old male Apc min/þ mice on a C57BL/6 genetic background (Jackson Labs) were treated with vehicle [phosphate-buffered saline (PBS)] or scopolamine butylbromide [(-)-N-butylscopolamine (NBS); 5 lg/g body weight/day; Butler Animal Health Supply, Dublin, OH] for 8 weeks, both administered using subcutaneous osmotic minipumps (Alzet model #2004; DURECT, Cupertino, CA). Alzet mini-osmotic pump #2004 is rated for 4 weeks of drug delivery. After the initial 4 weeks of use, the pumps were removed, discarded and replaced with new freshly loaded pumps. Hence, drug treatment (PBS or Muscarinic receptor subtype-3 in Apc min/þ mice scopolamine butylbromide) was for a total of 8 weeks. Pump insertion surgeries were performed aseptically. After pump insertion, we monitored all mice daily. No mice experienced local infection or pump migration. Pump tip extrusion was seen in a few mice; in these animals, to prevent pump loss and maintain drug delivery, pumps were repositioned immediately and the overlying skin was closed using Vetbond followed by local betadine treatment. At 14 weeks of age, blood hemoglobin was measured (ITC HgbPro Hemoglobin Monitor; Medical Resources, Lewis Center, OH), animals were euthanized and the small intestine was dissected and examined as described above.
Histopathology and immunohistochemistry
Formalin-fixed paraffin-embedded small intestine was sectioned and stained with hematoxylin and eosin and Alcian blue (to identify goblet cells) using standard techniques. Stained sections were reviewed by a senior pathologist (C.D.), masked to genotype and treatment. Adenomas were defined as low and high grades according to the consensus recommendations (8) . Numbers of crypt, Paneth and goblet cells were counted as a percentage of total cells in normal intestinal epithelium (not adenomas) in at least five high-power fields from 10 to 15 randomly selected sections from five to seven mice per genotype (all intact crypts within the field were evaluated). For b-catenin immunohistochemistry, sections from 10 mice per genotype were deparaffinized and rehydrated, followed by antigen unmasking in citrate buffer. Slides were blocked and incubated with primary antibody (b-catenin; BD Biosciences, Franklin Lakes, NJ) overnight, followed by incubation with biotinylated secondary antibody and processing with the Vectastain Elite ABC Kit (Vector Labs, Burlingame, CA) as per the manufacturer's instructions. Sections were counterstained with hematoxylin. The numbers of cells with b-catenin nuclear staining were counted as a percentage of total cells in at least five highpower fields from 10 to 15 sections from five to seven mice per genotype (all intact crypts within the field were evaluated in mice with WT Apc and Chrm3, Apc min/þ mice with WT Chrm3 and Apc min/þ mice with homozygous deletion of Chrm3; all adenomas within the field were evaluated in Apc min/þ mice with WT and deleted Chrm3). To avoid uncertainty, nuclear b-catenin staining was graded as either absent or present (heavy blue/gray staining). In all histological evaluations, only intact crypts and villi were evaluated by investigators masked to genotype.
Statistical analysis
The t-test was used for pair-wise comparisons and analysis of variance with Tukey's honestly significant difference test for testing the overall significance of more than two groups. Pearson correlation analysis was used to measure the association between two different measurements. For parameters not normally distributed, the non-parametric Mann-Whitney test was used with Bonferroni correction for multiple comparisons. Statistical significance was set at P , 0.05.
Results
When we crossed Apc min/þ mice on a C57BL/6 background with Chrm3 À/À mice on the same genetic background, we obtained only a very small number of Apc min/þ Chrm3 À/À mice, most probably due to reduced fertility of the congenic Chrm3 À/À mutant mice. We therefore crossed Apc min/þ on a C57BL/6 background with Chrm3 À/À mice on an SvEv:CF1 background. Interbreeding proved highly successful; effects of Chrm3 deficiency were evaluated in mice with the resulting hybrid genetic background. To avoid additional confounding variables, to determine the effect of Chrm3 gene deletion on intestinal tumor production, we compared weights, tumor number and size and other variable in F2 littermates.
Targeted deletion of the Chrm3 gene produces mice that are 'hypophagic and lean' (16) . The same was observed in Apc min/þ mice with homozygous Chrm3 deficiency; from 6 weeks of age until euthanasia at 12 weeks, Apc min/þ Chrm3 À/À mice weighed $20% less than Apc min/þ Chrm3 þ/þ and Apc min/þ Chrm3 þ/À littermates (P , 0.01, Figure 1A) . However, the small intestine was slightly longer in Chrm3-deficient compared with control mice; 37.4 ± 1.2 cm in Apc min/þ Chrm3 þ/þ , 40.2 ± 0.5 cm in Apc min/þ Chrm3 þ/À and 41.2 ± 0.5 in Apc min/þ Chrm3 À/À mice (P , 0.02 and 0.001, respectively, for Chrm3 þ/À and Chrm3 À/À versus. Chrm3 þ/þ ). At euthanasia, the livers of all were examined for evidence of liver injury (10) ; in all test mice used in these studies, including those treated with scopolamine butylbromide, the livers appeared grossly normal.
The number of small intestinal tumors was reduced in Apc min/þ Chrm3 À/À mice compared with Apc min/þ Chrm3 þ/À and Apc min/þ Chrm3 þ/þ littermates with wild-type or heterozygous expression of Chrm3 ( Figure 1B) . A clear gene 'dose effect' was observed. Apc min/þ Chrm3 þ/À mice showed fewer tumors than Apc min/þ Chrm3 þ/þ mice but more tumors than Apc min/þ Chrm3 À/À mice; Muscarinic receptor subtype-3 in Apc min/þ mice tumor numbers for Apc min/þ Chrm3 þ/þ , Apc min/þ Chrm3 þ/À and Apc min/þ Chrm3 À/À mice were 74.1 ± 11.0, 42.3 ± 7.9 and 18.5 ± 5.6, respectively (mean ± SE; Figure 1C ). Most tumors were detected in the distal small intestine and in each small intestinal segment, fewer tumors were observed in Apc min/þ Chrm3 À/À compared with Apc min/þ Chrm3 þ/þ mice ( Figure 1D ). In Apc min/þ Chrm3 À/À mice, reduced tumor volume was even more striking. Total small intestinal tumor volumes for Apc min/þ Chrm3 þ/þ , Apc min/þ Chrm3 þ/À and Apc min/þ Chrm3 À/À mice were 216.5 ± 47.5, 84.2 ± 13.7 and 41.3 ± 5.7 mm 3 , respectively ( Figure 2A ). Tumor volume, which increased progressively from the proximal to distal small intestine, was reduced by Chrm3 deficiency in each intestinal segment ( Figure 2B ). These findings indicate that Chrm3 expression plays a strong role in intestinal tumor promotion. In Apc min/þ Chrm3 þ/þ mice, both low-( Figure 2C , a and b) and high-grade adenomas ( Figure 2C , c and d) were observed (8) . Lowgrade adenomas were more common ( Figure 2D) . Nonetheless, only low-grade adenomas were observed in distal intestinal segments from Apc min/þ Chrm3 À/À mice; no high-grade adenomas were detected ( Figure 2C , e and f, Figure 2D ). These results indicate that in Apc min/þ mice, Chrm3 deficiency reduces tumor number and size and the degree of dysplasia.
We used immunohistochemistry to detect nuclear accumulation of b-catenin, a key step in the development of intestinal neoplasia (15) . In Apc þ/þ Chrm3 þ/þ mice, intestinal epithelial b-catenin expression was primarily membranous and weakly cytoplasmic ( Figure 3A) . In contrast, in both adenomas and normal-appearing epithelium from Apc min/þ Chrm3 þ/þ mice, we observed increased nuclear accumulation of b-catenin ( Figure 3A , middle panel-see inset). Admittedly, nuclear b-catenin staining, which was apparent under the microscope, is more difficult to appreciate in photographs. Nuclear b-catenin staining was reduced in both adenomas and normal-appearing intestinal epithelium from Apc min/þ Chrm3 À/À mice ( Figure 3A, right panel) . When nuclear b-catenin staining was quantified and characterized by genotype ( Figure 3B) , it was apparent that changes in cellular distribution of b-catenin were more robust in adenomas than in normal tissue. Significant reduction in nuclear b-catenin staining was observed in adenomas from Apc min/þ Chrm3 À/À compared with those from Apc min/þ Chrm3 þ/þ mice (P , 0.02) ( Figure 3B) .
b-Catenin signaling modulates the development of intestinal secretory cell lineages (e.g. Paneth and goblet cells) (15) . As a consequence, in addition to inducing intestinal neoplasia, Apc gene mutation alters the architecture of non-neoplastic intestinal epithelium (17) . We were curious to determine whether in addition to its effects on tumor production, genetic deletion of Chrm3 would also alter the numbers of crypt, Paneth and goblet cells in Apc min/þ mice. To determine if Chrm3 deficiency altered total crypt cellularity, and the numbers of Paneth and goblet cells, we stained sections of intestinal mucosa from 5 to 7 mice per genotype and counted cells as described in Materials and Methods. Many approaches are used for this purpose; there is no clear consensus defining the correct or best approach, and there are few comparisons of different approaches. These important issues are discussed elegantly in The Biologyof Epithelial Cell Populations by Wright et al. (18) . We agree with caveats regarding these approaches raised therein. Nonetheless, methodology used in the present work is consistent with those used in recent years by most investigators in the field. Clearly, intra-tumor and inter-animal heterogeneity exists, but we believe that the relatively large numbers of sections and high-power fields examined in tissues from 5 to 7 mice per genotype reasonably accounts for this. Moreover, investigators evaluating histological sections were masked to treatment conditions (e.g. genotype).
Crypt cellularity was greater in Apc min/þ Chrm3 þ/þ mice (57.4 ± 1.6 cells/crypt) compared with Apc þ/þ Chrm3 þ/þ mice (38.2 ± 1.1 cells/crypt) but indistinguishable from wild-type in Apc min/þ Chrm3 À/À mice (37.6 ± 1.0 cells/crypt; P , 0.01 compared with Apc min/þ Chrm3 þ/þ mice). Likewise, Paneth cell number was greater in Apc min/þ Chrm3 þ/þ mice (3.1 ± 0.1 Paneth cells/crypt) compared with Apc þ/þ Chrm3 þ/þ mice (2.2 ± 0.1 Paneth cells/crypt) (P , 0.01) but indistinguishable from wild type in Apc min/þ Chrm3 À/À mice (2.2 ± 0.1 Paneth cells/crypt; P , 0.01 compared with Apc min/þ Chrm3 þ/þ mice). Compared with Apc þ/þ Chrm3 þ/þ mice, villi in Apc min/þ Chrm3 þ/þ mice had fewer goblet cells. Strikingly, goblet cell number was restored in Apc min/þ Chrm3 À/À mice ( Figure 3C and D) . Collectively, these findings indicate that Chrm3 deficiency 'normalizes' small intestinal mucosal cellular proliferation and development in Apc min/þ mice.
We next determined whether reducing muscarinic receptor activation with a chemical inhibitor had the same effects as reducing Chrm3 expression. Because our previous work indicated that murine intestinal epithelial cells express both Chrm1 and Chrm3 (9), we used scopolamine butylbromide (NBS; 5 mg/kg body weight/day), a nonsubtype-selective muscarinic receptor antagonist. Compared to treatment with PBS, 8 weeks of NBS infusion did not alter mouse weight (P 5 0.58) or length of the small intestine (P 5 0.36). In Apc min/þ mice, occult blood loss from intestinal tumors causes anemia (16) . Blood hemoglobin in mice immediately before euthanasia was modestly, but significantly, greater in NBS-treated (10.3 ± 0.3 g/dl) compared with PBS-treated mice (9.2 ± 0.3 g/dl) (P 5 0.005; Figure 4A ). Moreover, NBS-treated Apc min/þ mice had significantly fewer small intestinal tumors than control animals (29.0 ± 2.0 versus. 37.1 ± 3.3; P 5 0.027; Figure 4B ). Compared with changes in tumor number, NBS treatment more robustly reduced tumor volume (49.1 ± 4.2 versus 76.1 ± 9.3 mm 3 ; P 5 0.004; Figure 4C ) and significantly reduced the fraction of intestinal tumors with volume .2 mm 3 (P 5 0.001; Figure 4D ). Collectively, these findings indicate that treatment of Apc min/þ mice with NBS, a chemical inhibitor of muscarinic receptor activation, reduces both small intestinal tumor number and size. As observed with Chrm3 gene ablation, NBS treatment more efficaciously reduced tumor size compared with tumor number; NBS treatment reduced the number of large adenomas (.2 mm 3 ) by $50% (Figure 4D) . 
Discussion
In the current study, we show in Apc min/þ mice that genetic ablation of Chrm3 attenuates intestinal tumor number and size and measures of tumor initiation and promotion, respectively (19, 20) , without the potential confounder of azoxymethane-induced liver toxicity (10) . Moreover, treating mice with a chemical inhibitor of muscarinic receptor activation also attenuated intestinal neoplasia, albeit not as effectively as Chrm3 gene ablation. Collectively, these findings are consistent with a key role for muscarinic receptor activation in both the initiation and promotion of intestinal neoplasia.
For the genetic ablation experiments, to obtain sufficient quantities of mice to analyze effects of Chrm3 deficiency, we bred mice with a mixed C57BL/6:SvEv:CF1 genetic background. Although this breeding strategy was highly successful at producing required numbers of animals, we acknowledge that genetic heterogeneity is a limitation. Moreover, in mice of this genetic background nothing is known about the expression of modifiers of the Min/þ phenotype (21) . Nonetheless, our data indicate that the Chrm3 genotype is dominant over Min modifiers, if any. An additional limitation is that the animals compared in the present study did not have intestine-selective knockout of Chrm3. Hence, it is possible that Chrm3 ablation in other tissues, e.g. stromal, neuronal or inflammatory cells, plays a role in the observed reduction in tumor number and size.
To block muscarinic receptor activity, we selected scopolamine butylbromide (NBS), a quaternary ammonium derivative of scopolamine that does not cross the blood-brain barrier and therefore does not cause central nervous system side effects (22, 23) . Several factors may limit the efficacy of NBS treatment compared with Chrm3 gene ablation. NBS treatment started when the mice were 6 weeks old, whereas effects of gene ablation commence in utero. Whereas gene ablation results in absence of Chrm3 expression, NBS, even when administered continuously by osmotic minipump, is not likely to completely block muscarinic receptors. It is also possible that longterm muscarinic receptor blockade results in up-regulation of Chrm3. Studies using atropine to block muscarinic receptors in the central nervous system indicate up-regulation of Chrm1, 3 and 4 (24) (25) (26) (27) (28) . Although similar studies have not been conducted in the gastrointestinal tract, it is possible that up-regulation of muscarinic receptors may explain, in part, the limited efficacy of scopolamine butylbromide on intestinal tumor initiation and promotion in our test mice. Finally, NBS inhibits activation of all muscarinic receptor subtypes and neither gene ablation nor anti-muscarinic receptor treatment targeted intestinal epithelial cells specifically. Despite these limitations, the NBS experiments provide a proof-of-concept that treatment with an inhibitor of muscarinic receptor activation can attenuate intestinal tumor formation and growth.
In humans and mice, studies indicate that high-fat diets and increased body weight are associated with an elevated risk of colon neoplasia (29) . Hence, it is of interest that mice with homozygous Chrm3 deletion weighed $20% less than Apc min/þ Chrm3 þ/þ littermates. However, as shown in Figure 1 , mice that were heterozygous for Chrm3 expression weighed the same as mice with WT Chrm3 but had a statistically significant reduction in both tumor number ( Figure 1C ) and size (Figure 2A ). In the experiments using scopolamine butylbromide to block receptor activation, there was no difference in body weight compared with mice treated with vehicle but again, there was a statistically significant reduction in tumor number and size ( Figure 4B and C) . Collectively, these observations indicate that mouse body weight did not play a meaningful role in our key observations and differences in tumor initiation and promotion were solely a consequence of Chrm3 expression.
In summary, our results indicate that altered small intestine mucosal cellularity and tumor development characteristic of Apc min/þ mice requires functional Chrm3. Genetic or pharmacological inhibition of muscarinic receptor activity attenuated small intestinal adenoma formation. Future studies will address the molecular basis for convergence of muscarinic receptor and b-catenin signaling. Our novel findings suggest that muscarinic receptor antagonists may prove useful in the prevention or treatment of intestinal neoplasia in humans. However, based on the modest efficacy of scopolamine butylbromide, more efficacious approaches to inactivate intestinal muscarinic receptors and possibly co-therapy with drugs that target other signaling pathways will probably be required.
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